What is Ribometrix?
Ribometrix is at the vanguard of a new era in drug discovery, focusing on the development of small molecule therapeutics designed to modulate cellular RNA and correct the production of disease-causing proteins. By integrating established drug discovery methodologies with cutting-edge RNA-targeting technologies, the company aims to address a broad spectrum of diseases. Ribometrix actively engages in strategic collaborations to advance its mission of RNA modulation through small molecules. Situated in North Carolina's Research Triangle Park, the company is a key player in a field with the potential to revolutionize medicine.
How much funding has Ribometrix raised?
Ribometrix has raised a total of $45.3M across 3 funding rounds:
Angel/Seed
$7.5M
Series A
$30M
Other Financing Round
$7.8M
Angel/Seed (2017): $7.5M with participation from SV Health Investors, Hatteras Venture Partners, MP Healthcare Venture Management, and Dementia Discovery Fund
Series A (2018): $30M led by M Ventures
Other Financing Round (2019): $7.8M supported by Illumina Ventures and Dementia Discovery Fund
Key Investors in Ribometrix
Illumina Ventures
Illumina Ventures is a prominent investor in genomics and precision health, dedicated to fostering innovation that enhances human health. They support companies advancing life science research and biopharmaceutical drug development.
SV Health Investors
SV Health Investors is a specialized firm that backs innovative healthcare and life science companies, providing capital and sector expertise to support growth and value creation from early stages.
M Ventures
M Ventures, the strategic venture capital arm of Merck, invests globally in innovative technologies and products with the potential to impact core business areas, actively supporting portfolio companies towards commercial success.
What's next for Ribometrix?
The recent major strategic investment, coupled with the substantial overall funding of $45.3M, positions Ribometrix for accelerated growth and expansion. This capital infusion is expected to fuel further research and development, enhance its collaborative partnerships, and potentially scale its therapeutic pipeline. The company's focus on RNA modulation through small molecules represents a significant advancement in addressing previously intractable diseases, suggesting a trajectory towards clinical validation and market entry.
See full Ribometrix company page
